22 April, 2008 -
SkyePharma PLC (LSE: SKP) announces that it has entered into an exclusive Development, Distribution and License Agreement for Flutiform(TM), its lead development product for the treatment of asthma, with
Kyorin Pharmaceutical Co., Ltd., a subsidiary of Kyorin Co., Ltd. for Japan. SkyePharma will receive signing, development and approval milestones worth several millions of pounds plus a high mid-single digit royalty on sales.
The development costs associated with obtaining approval for the Japanese market will largely be met by Kyorin, which is responsible for clinical trials and regulatory submissions. Development is expected to take several years...
SkyePharma's Press Release -
